WHO pauses trial of HCQ in Covid-19 patients

the decision to suspend trials of hydroxychloroquine had been taken out of “an abundance of caution

268
WHO

Last Updated on November 6, 2020 by The Health Master

Geneva

The World Health Organization has suspended testing the malaria drug hydroxychloroquine (HCQ) in COVID-19 patients due to safety concerns, WHO Director General Tedros Adhanom Ghebreyesus said on Monday.

Hydroxycholoroquine has been touted by Donald Trump and others as a possible treatment for the disease caused by the novel coronavirus. The US President has said he was taking the drug to help prevent infection.

“The executive group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity trial while the safety data is reviewed by the data safety monitoring board,” Tedros told an online briefing.

Also read: US company trials coronavirus vaccine in Australia

He said the other arms of the trial — a major international initiative to hold clinical tests of potential treatments for the virus — were continuing. The WHO has previously recommended against using hydroxychloroquine to treat or prevent coronavirus infections, except as part of clinical trials.

Dr. Mike Ryan, head of the WHO emergencies programme, said the decision to suspend trials of hydroxychloroquine had been taken out of “an abundance of caution”. — Reuters

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.